Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM31WQC)

• Drug Name: Maxy-10 Drug Info
• Synonyms: Optimized interferon beta, Maxygen; Beta-interferon (optimized), Maxygen

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DM31WQC

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon-beta (IFNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PEGylated IFN beta 1-a	DMRH0D5	Type-2 diabetes	5A11	Approved	[3]
PLEGRIDY	DMAKXW9	Multiple sclerosis	8A40	Approved	[4]
Interferon beta-1a	DM1A6RV	Multiple sclerosis	8A40	Approved	[5]
FP-1201	DM823WQ	Acute lung injury	NB32.3	Phase 3	[6]
NU-100	DMA16IL	Multiple sclerosis	8A40	Phase 3	[7]
Biferonex	DM57B9J	Multiple sclerosis	8A40	Phase 3	[8]
AZ-01, PEGylated interferon-beta	DMHFUJT	Multiple sclerosis	8A40	Phase 2	[7]
PF-06823859	DM8C1H4	Dermatomycosis	EA60	Phase 2	[9]
Interferon beta 1a	DMQSA7H	Discovery agent	N.A.	Phase 2	[10]
ARX-424	DM4CZ2Y	Multiple sclerosis	8A40	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-beta (IFNB1)	TT4TZ8J	IFNB_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016147)
• [2] US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators.
• [3] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
• [7] PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
• [8] Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.